...what is the chance that after 'major' random errors such good efficacy results?
The only chance is that the mix up occurred only in the two treatment arms.
Not that that would change the bottom line for the PIIb trial or stock holders. The trial is facacta, the company's future appears bleak.
With multiple ISTs ongoing and a PII in pancreatic cancer due to report out by the end of the year, they have a lot more to investigate than this one trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.